References
- Torre LA , BrayF , SiegelRLet al. Global cancer statistics, 2012 . CA: Cancer J. Clin.65 ( 2 ), 87 – 108 ( 2012 ).
- Aiello M , VellaN , CannavoCet al. Role of genetic polymorphisms and mutations in colorectal cancer therapy . Mol. Med. Report4 ( 2 ), 203 – 208 ( 2011 ).
- Thirion P , MichielsS , PignonJPet al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis . J. Clin. Oncol.22 ( 18 ), 3766 – 3775 ( 2005 ).
- Kelly H , GoldbergRM . Systemic therapy for metastatic colorectal cancer: current options, current evidence . J. Clin. Oncol.23 ( 20 ), 4553 – 4560 ( 2005 ).
- Woynarowski JM , FaivreS , HerzigMCet al. Oxaliplatin-induced damage of cellular DNA . Mol. Pharmacol.58 ( 5 ), 920 – 927 ( 2000 ).
- Alcindor T , BeaugerN . Oxaliplatin: a review in the era of molecularly targeted therapy . Curr. Oncol.18 ( 1 ), 18 ( 2011 ).
- Graham MA , LockwoodGF , GreensladeDet al. Clinical pharmacokinetics of oxaliplatin: a critical review . Clin. Cancer Res.6 ( 4 ), 1205 – 1218 ( 2000 ).
- Funke S , BrennerH , Chang-ClaudeJ . Pharmacogenetics in colorectal cancer: a systematic review . Pharmacogenomics9 ( 8 ), 1079 – 1099 ( 2008 ).
- Lu X , XiaoS , JinCet al. ERCC1 and XPD/ERCC2 polymorphisms’ predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis . J. Clin. Lab. Anal.26 ( 1 ), 10 – 15 ( 2012 ).
- Yin M , YanJ , Martinez-BalibreaEet al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis . Clin. Cancer Res.17 ( 6 ), 1632 – 1640 ( 2011 ).
- Qian YY , LiuXY , WuQet al. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies . Asian Pac. J. Cancer Prev.15 ( 19 ), 8383 – 8390 ( 2014 ).
- Ye F , LiuZ , TanAet al. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis . Cancer Chemother. Pharmacol.71 ( 3 ), 733 – 740 ( 2013 ).
- Hayden JA , Van Der WindtDA , CartwrightJLet al. Assessing bias in studies of prognostic factors . Ann. Intern. Med.158 ( 4 ), 280 – 286 ( 2013 ).
- De Mattia E , CecchinE , ToffoliG . Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: towards targeted personalized therapy . Drug Resist. Updat.20 , 39 – 70 ( 2015 ).
- Yu JJ , LeeKB , MuCet al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene . Int. J. Oncol.16 ( 3 ), 555 – 560 ( 2000 ).
- Chen ZP , MalapetsaA , MonksAet al. Nucleotide excision repair protein levels vis-a-vis anticancer drug resistance in 60 human tumor cell lines . Ai Zheng21 ( 3 ), 233 – 239 ( 2002 ).
- Lunn RM , HelzlsouerKJ , ParshadRet al. XPD polymorphisms: effects on DNA repair proficiency . Carcinogenesis21 ( 4 ), 551 – 555 ( 2000 ).
- Wang Y , SpitzMR , ZhuYet al. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity . DNA Repair2 ( 8 ), 901 – 908 ( 2003 ).
- Stoehlmacher J , GhaderiV , IobalSet al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer . Anticancer Res.21 ( 4B ), 3075 – 3079 ( 2001 ).
- Suh KW , KimJH , Kim DoYet al. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann. Surg. Oncol. 13 ( 11 ), 1379 – 1385 ( 2006 ).
- Wu H , XuC , ChenGet al. x-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis . J. Gastroenterol. Hepatol.29 ( 5 ), 926 – 933 ( 2014 ).
- Watson MA , StewartRK , SmithGBet al. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution . Carcinogenesis19 ( 2 ), 275 – 280 ( 1998 ).
- Cortejoso L , Lopez-FernandezLA . Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients . Pharmacogenomics13 ( 10 ), 1173 – 1191 ( 2012 ).